FPA Women’s Health is the largest independent family planning service network in the United States, and the Twirla (levonorgestrel and ethinyl estradiol) transdermal system is now the exclusive patch dispensed within FPA clinics in California Impact of availability through FPA Women’s Health is...
Agile Plans to Increase Twirla prescriptions filled through telemedicine platforms that utilize vitaCare, such as Twentyeight Health™ Partnership Expected to Augment Future Growth in the Retail Channel, the Company’s Most-Profitable Channel Expanding Commercial Reach through Strategic Partnerships...
PRINCETON, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the closing of its previously announced public offering of an aggregate of 1,896,286 shares of its common stock (or...
PRINCETON, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the pricing of its public offering of an aggregate of 1,896,286 shares of its common stock (or pre-funded warrants in lieu...
Twirla Delivers Single-Quarter Records for Retail and Non-Retail Demand; Both Channels Up 20% in First Quarter 2023 vs Fourth Quarter 2022 Total OPEX down 8% in First Quarter 2023 vs Fourth Quarter 2022 Company Reaffirms Expected Full Year 2023 Net Revenue in Range of $25-$30 Million Management to...
Live Conference Call and Webcast at 4:30 p.m. ET PRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report first quarter 2023 financial results after the market close on Thursday, May 11, 2023....
PRINCETON, N.J., April 28, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced preliminary expectations for first quarter 2023 Twirla ® demand, net revenue and operating expenses. Expected First Quarter 2023 Performance Update (Unaudited)...
PRINCETON, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it has received a notification letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”), informing the Company...
PRINCETON, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile”), a women's healthcare company, today announced that its board of directors approved a 1-for-50 reverse stock split, to be effective 4:00 p.m. on Monday, April 10, 2023....
Fourth Quarter 2022 Net Revenue Increased 33% from Third Quarter 2022 While GAAP Quarter-Over-Quarter OPEX Decreased 55% and Non-GAAP OPEX Remained Unchanged Twirla Demand and Factory Sales Up 25% and 30% Respectively in Fourth Quarter 2022 vs Third Quarter 2022 Company Reaffirms Expected Full Year...
